BIOPHARMA BOSTON
THE FUTURE OF ALLIANCES STARTS HERE
November 9-11, 2026
Register Now
Early Bird Discount Ends September 25
November 9-11, 2026
Register Now
Early Bird Discount Ends September 25
ASAP BioPharma Boston
The Future of Alliances Starts Here
Menu
What to expect
Three days built by practitioners, for practitioners. Every session is chosen for its real-world relevance, which means you'll leave with strategies, frameworks, and connections you can actually use.
Sessions that reflect the work you do
The 2026 program covers what's actually changing the job: AI moving from experiment to daily toolkit, governance models stretching to handle three, four, or more partners at once, and alliance leaders being asked to own value realization, not just process. No product pitches. No purely theoretical topics. Just the real work our community comes for.
What you'll walk away with
- Actionable strategies from 70+ alliance leaders and practitioners
- High-value connections with peers from pharma, biotech, academia, and beyond
- 12 professional development hours toward CA-AM or CSAP certification renewal
“Networking with peers who truly understand the art and science of alliances was game-changing. I connected with leaders across industries whose insights have reshaped how our teams think about collaboration and value creation.” ~ Kristin Rosner, PhD, CSAP, CA-AM, Senior Director, Global R&D Alliance Management, Takeda
2027 Conference Co-Chairs and 2026 Featured Speakers

Aram Donigian, Clinical Professor of Business Administration, Faculty Director, Tuck Business Bridge Program, Dartmouth
Aleksey Gerasyuto, PhD, Senior Vice President, Discovery & Preclinical Development Sciences, Schrödinger
Who's Attending
Join alliance and partnership leaders from more than 120 organizations across pharma, biotech, academia, and consulting.
- AbbVie
- AbCellera
- Absci
- AchieveUnite
- ADARx
- Ailux
- allianceboard
- Allorion Therapeutics
- Alloy Therapeutics
- Alnylam Pharmaceuticals
- Alzheimer's Research UK UCL Drug Discovery Institute
- Amgen
- Argo Biopharmaceuticals
- Arrowhead Pharmaceuticals
- Astellas
- AstraZeneca
- Beam Therapeutics
- BeOne Medicines
- Biogen
- BioNTech
- Boehringer Ingelheim
- Boston Children's Hospital
- Boston Consulting Group
- BridgeBio
- Bristol Myers Squibb
- C4 Therapeutics
- Carberry Consulting
- CAS
- Chiesi Farmaceutici S.p.A.
- Daiichi Sankyo
- DNDi
- Douglas Pharmaceuticals
- Dyno Therapeutics
- Eisai
- Electrome
- Eli Lilly and Company
- EMD Serono
- Enable Injections
- Everest Medicines
- Evopoint Biosciences
- Flagship Pioneering
- Foresight Diagnostics
- Genevant Sciences
- Genmab
- Gilead Sciences
- GondolaBio
- GSK
- Guardant Health
- Harvard University
- Houston Methodist Hospital
- Illumina
- IMMvention Therapeutix
- Incyte
- Inpart
- Integrated Project Management (IPM)
- Intercellular
- Ionis Pharmaceuticals
- Isomorphic Labs
- Jazz Pharmaceuticals
- Johnson & Johnson Innovative Medicine
- Kailera Therapeutics
- KDodd Consulting
- KPMG
- Kyorin Pharmaceutical
- Kyowa Kirin
- LifeArc
- Lundbeck
- Lygature
- mAbxience
- Mass General Brigham
- Merck
- Merck Sharp and Dohme (MSD)
- Moderna
- n-Lorem Foundation
- Nabla Bio
- Nationwide Children's Hospital
- Novartis
- Novo
- NS Pharma
- Nurix Therapeutics
- Nutriquest
- Ono Pharmaceutical
- Oxford University
- Partners4Patients Foundation
- Pfizer
- Pierre Fabre
- Pillar Biosciences
- PPAM Solutions
- Precede BioSciences
- Psivant Therapeutics
- PwC
- Quotient Therapeutics
- SanegeneBio
- Sanofi
- Schrödinger
- Servier
- Shionogi
- Simcere Pharmaceutical
- Soufflé Therapeutics
- Stanford University
- Stealth Biotech
- Sumitomo
- Supernus
- Symbix Consulting
- Takeda Pharmaceuticals
- Teva Pharmaceuticals
- TFC BioSciences
- The Broad Institute of MIT and Harvard
- The Rhythm of Business
- Thea Open Innovation
- Tuck School of Business at Dartmouth College
- University College London
- University of Cambridge
- University of Illinois - Chicago
- University of Michigan
- Upsher-Smith Laboratories
- Valo Health
- Vantage Partners
- Voyager Therapeutics
- Wave Life Sciences
- X-Chem
- Xencor
- Xtalpi
- Zealand Pharma
2026 Program
Sessions and times are subject to change
| 1:00-5:00 | Board of Directors Meeting (Invite only) |
| 6:00-8:00 | Board of Directors Dinner (Invite only) |
| 8:00-2:30 |
Alliance Essential Course (separate registration and fee required) |
| 8:00-2:30 | Applied Alliance Management Course formerly called the CA-AM Exam Prep (separate registration and fee required) Instructor: Swati Prasad, PhD, CSAP CA-AM, Alloy Therapeutics |
| 8:00-2:30 | Alliance Strategy & Leadership Course (separate registration and fee required) Instructor: Ann Trampas, CSAP, CA-AM, University of Illinois at Chicago |
| 8:00-2:30 |
Mastering Alliance Management: Driving Clarity, Value, and Influence in Alliance Leadership Course (separate registration and fee required) Sponsored by Amgen Instructors: Tracy Blois, PhD, Amgen, Vickie Dalton, PsyD, Clinical Psychologist, Katherine Kendrick, CSAP, CA-AM, Jazz Pharmaceuticals, Nick Palmer, Oaklin, and David Thompson, CSAP, CA-AM, BeOne Medicines |
| 8:30-11:30 | ASAP Advisory Council Meeting (w/ the Board of Directors) (Invite only) |
| 11:30-2:30 |
Executive Leadership Luncheon & Forum (Invite only) |
|
12:00-2:00 |
Boston Dine Around Town Kick off your BioPharma Boston experience with a casual lunch alongside a small group of fellow attendees. These intimate dine-arounds are a great way to connect and network before the conference begins. An additional fee applies. Sign up under Networking Add-Ons in the conference registration. |
DAY 1: ALLIANCE LEADERSHIP IN A CHANGING WORLD |
|
| 3:00-3:15 |
BioPharma Boston Kick-Off, Nicole Boston, CAE, CA-AM, ASAP; Katherine Kendrick, CSAP, CA-AM, Jazz Pharmaceuticals; Arne Wörn, Novartis |
| 3:15-3:45 |
101 - Extreme Negotiations |
|
3:45-4:15 |
102 - The New Geography of BioPharma Innovation: China and the Changing Deal Landscape Roel van den Akker, PwC The geography of biopharma innovation is being redrawn. China’s biotech ecosystem has rapidly evolved into a major source of globally competitive science and innovative assets, increasing cross-border licensing, investment, and partnership activity. For global biopharma companies, this evolution creates both significant opportunity and new complexity. Deal structures are changing, competition for assets is increasing, and regulatory, geopolitical, valuation, and execution considerations are becoming more important. Drawing on PwC’s perspective across the global biopharma deal environment, Roel van den Akker will examine the forces driving China’s emergence as a global innovation hub and what they mean for the next generation of cross-border partnerships. The session will explore what alliance and business leaders should understand, and the capabilities they will need to build, when evaluating opportunities, structuring partnerships, managing risk, and preparing for the next phase of global biopharma collaboration. |
|
4:15-4:30 |
Networking Break |
|
4:30-5:15 |
103 - Leading Strategic Alliances in the AI Era Brooke Paige, CSAP, CA-AM, Novartis, Tracy Blois, PhD, Amgen, Crystal Dillon, CA-AM , Eli Lilly, Fern McSorley, PhD, Isomorphic Labs & Petra Sansom, PhD, Beam Therapeutics Artificial intelligence is changing how organizations collaborate, make decisions, and manage strategic partnerships. For alliance leaders, AI now appears in the Alliance Management space in three ways: in how alliance teams work, within the partnerships they manage, and increasingly as the foundation of AI-centered alliances. Navigating all three requires new capabilities and a clear view of what technology cannot replace. Focusing on the first of the three themes, four alliance leaders from large pharma, a mid-sized biotech, and an AI-first discovery company will share what they see in daily practice. Panelists will discuss how organizations are approaching AI adoption within alliance teams, how AI is changing the nature of collaboration with partners, and how alliance managers can address governance, data stewardship, and ethical use as these tools enter joint work. |
|
5:15-5:45 |
104 - The External Forces No Alliance Can Ignore: How Policy, Pricing, & Geopolitics Are Reshaping Partnerships Mark Bolton, Jazz Pharmaceuticals The potential implementation of Most-Favored-Nation (MFN) pricing policies in the United States represents a significant shift in how domestic drug valuation and international market structures intersect. This session examines the technical relationship between foreign reference pricing systems, proposed U.S. MFN models, and commercial biopharmaceutical economics. Using objective policy data, we will analyze how pricing agreements established in major global markets can influence domestic rebates, net sales calculations, and joint venture contractual terms. Attendees will review practical frameworks for mapping regulatory exposure, coordinating international data sharing, and incorporating policy analysis into standard alliance governance to support long-term business planning. |
|
5:45-6:00 |
105 - Presentation of the Alliance Excellence Awards Katherine Kendrick, CSAP, CA-AM, Jazz Pharmaceuticals, and Nicole Boston, CAE, CA-AM, ASAP The ASAP Alliance Excellence Awards recognize outstanding achievement, leadership, and contributions within the alliance management community. These prestigious awards celebrate individuals who have demonstrated a commitment to advancing the profession and creating meaningful impact through strategic partnerships. Award Categories:
|
| 6:00-6:30 |
New Member & First Timer Reception |
| 6:00-8:00 |
Welcome and Awardee Celebration Reception (all invited) Sponsored by Jazz Pharmaceuticals Join for an evening celebrating our Alliance Excellence Award winners! Enjoy live jazz, hors d’oeuvres, and a signature cocktail while connecting with fellow attendees. Guests can also participate in Find Your Groove, an optional interactive networking activity designed to spark conversations and build new connections. |
| 6:00 - 7:00 |
Brooke's Boston Stroll (Run/Walk) - Free Activity
Lace up and explore Boston's rich history on foot with Brooke Paige and fellow attendees-whether you run, jog or walk, it's a perfect way to connect and energize. |
|
| 7:00-8:00 |
Networking Breakfast Sponsored by allianceboard
|
|
| 7:00-7:45 |
CSAP Breakfast (invite only)
|
|
DAY 2: AI, DIGITAL TRANSFORMATION, AND NEW INNOVATION MODELS |
||
| 8:10-8:20 |
Welcome Back, Katherine Kendrick, CSAP, CA-AM & Arne Wőrn, PhD
|
|
| 8:20-8:50 |
106 - The Science Behind Successful AI and Biopharma Alliances: Lessons from the Front Lines
Aleksey Gerasyuto, PhD, Schrödinger While traditional biopharma alliances often center on specific therapeutic assets, the rapid evolution of computational and AI-driven drug discovery has introduced a fundamentally new partnering paradigm. These alliances require a distinct approach, capitalizing on the synergistic strengths of each partner by combining the deep integration of proprietary technology with close, cross-functional team collaboration.
Drawing on Schrödinger’s extensive history of successful, large-scale collaborations with leading global pharma and biotech companies, this presentation will explore the unique anatomy of these partnerships. Aleksey will unpack the specific opportunities and challenges these collaborations present. Through real-world case studies, the presentation will highlight key learnings, common hurdles, and proven best practices for fostering AI-driven collaborative innovation
|
|
| 8:50-9:35 |
107 - Building Successful AI-Enabled Discovery Alliances Artificial intelligence (AI) and machine learning (ML) are reshaping drug discovery, accelerating innovation while introducing new partnership complexities. From business development negotiations through alliance execution, organizations must navigate evolving challenges around intellectual property, data governance, proprietary algorithms, and cross-functional collaboration. Success depends on balancing innovation with appropriate protections while aligning scientific, technology, and alliance management teams around shared objectives. In this interactive panel discussion, experienced pharmaceutical and biotechnology leaders will share practical strategies for structuring, launching, and managing AI-enabled discovery collaborations. Attendees will gain real-world insights into negotiating agreements, fostering trust and transparency, protecting valuable assets, and establishing governance practices that enable agile, productive partnerships capable of delivering long-term scientific and business value.
|
|
| 9:35-10:20 |
108 - The Future of Biopharma Partnering: AI, China and the Forces Reshaping Deals Patent expiries, emerging modalities, regulatory shifts and evolving patient engagement models are accelerating change across the biopharmaceutical industry. At the same time, advances in AI and the growth of China-originated innovation are creating new opportunities and influencing how companies approach dealmaking. In this session, KPMG’s Dana Hughes and Alasdair Milton will examine the forces reshaping the biopharma landscape and what they mean for partnering strategies. They will explore how companies can respond to a changing deal environment and build the alliances needed to turn emerging opportunities into transactions and lasting value. |
|
| 10:20-10:50 | Networking Break | |
|
10:50-11:30 |
BREAKOUTS | |
|
Track 1 AI, Digital Innovation & the Future of Alliance Management |
201 - Building AI-Ready Alliances: “Before the Bots” Essential Steps for Success Many alliance management teams rush to adopt AI solutions without first establishing a solid foundation. This session outlines the critical steps to prepare for AI integration: organizing data into reliable "sources of truth," standardizing terminology across stakeholders, and collaborating with IT to address pain points. Attendees will learn to evaluate current data landscapes and develop capabilities that enhance the clarity, reliability, and scalability of AI insights. Rather than viewing AI as a shortcut, this talk provides a practical roadmap for creating the necessary structure, discipline, and shared language to maximize AI's value in alliance management. The session will feature examples of AI tools co-developed by AbbVie Global Alliances and Business Technology Solutions. |
|
|
Track 2 Alliance Leadership & Value Creation |
301 - From One to Many: Developing a Partnerhip Portfolio |
|
|
Track 3 Complex Partnerships, Governance & Cross Sector Collaborations |
401 - Novel Governance Models for Scaling AI-Enabled Multi-Partner Ecosystems Swati Prasad, PhD, CSAP, CA-AM, Alloy Therapeutics AI-enabled collaborations are reshaping the biopharma partnership landscape, demanding governance models that extend beyond traditional bilateral structures. Many current models are optimized for bilateral partnerships, creating operational friction in dynamic, multi-stakeholder ecosystems involving technology, analytics, infrastructure, and research partners. This session explores practical lessons from scaling complex, multi-party alliances, addressing governance overload, IP ambiguity, partner engagement challenges, AI-enabled health metrics, and data-sharing complexity. Through case studies and interactive exercises, attendees will learn how novel modular governance structures and scalable decision frameworks can enhance alignment and collaboration outcomes. Participants will leave with tools to assess alliance scaling risks and redesign governance for adaptive AI-enabled partnerships. This session moves beyond conceptual frameworks to explore the real-world implementation challenges of AI-enabled alliances. |
|
|
Track 4 Global Collaboration, Discovery Partnerships & Academia |
501 - Overcoming Challenges and Building High-Impact Academic Alliances Fabienne Furt, PhD, CA-AM, Boston Childen's Hospital, Kimberly Griffin, PhD, Stanford University, Sabrina Kamran, PhD, CA-AM, Boston Children's Hospital, Matthew Moscato, Nationwide Children's Hospital, & Seohee You, PhD, University of Michigan Managing alliances in academic settings presents unique challenges due to complex organizational structures. While some institutions have dedicated alliance managers, many professionals juggle multiple roles, such as technology transfer and program management, leading to misalignment and slower execution. Academic institutions consist of various departments and labs, resulting in distributed decision-making and diverse incentives. This panel session offers practical approaches to building successful, high-impact alliances with academic partners by understanding their organizational structures and strategic priorities. Participants will learn to manage expectations, identify suitable partners, and align academic priorities like publications and funding with industry objectives. Building relationships beyond the scientific team, including tech transfer and department leadership, is crucial for maintaining successful alliances. Attendees will gain insights into managing data-sharing, IP complexity, and stakeholder coordination, ensuring alignment with industry partner objectives and fostering a collaborative environment. |
|
|
11:30-12:45 |
Lunch Sponsored by inpart | |
|
11:30-12:45 |
Academic Alliances Peer Group Lunch
Join Michelle Gardner, CA-AM, Co-Chair of the ASAP Academic Alliances Working Group and Director of Industry Partnerships & Engagement at Northeastern University, and Christine Jost, PhD, CA-AM, Head of Academic Alliances at Novartis, for an informal lunch and discussion about the group’s current initiatives and future priorities. Connect with colleagues working in academic alliances to share challenges, exchange best practices, and explore ideas for how the working group can best support the community. All conference attendees are welcome! |
|
|
12:45-12:50 |
Welcome Back, Katherine Kendrick, CSAP, CA-AM & Arne Wőrn, PhD | |
|
12:50-1:20 |
109 - Academic Innovation Partnerships: Turning Discovery Into Impact Scientific discovery is advancing at an unprecedented pace, fueled by breakthroughs in AI, data science, genomics and emerging technologies. Yet the greatest innovations will only reach patients through strong partnerships that connect academics, start-ups, healthcare systems, investors, and the biopharma industry. Drawing on Harvard Medical School’s experience at the forefront of technology transfer and innovation, the talk will cover how the biomedical innovation landscape is evolving and how cross-sector collaboration is becoming the foundation for translating scientific discovery. |
|
|
1:20-2:05 |
110 - Bridging Organizational Differences: What Industry and Academia Need from Each Other Great science may bring industry and academia together, but it doesn't guarantee a successful partnership. Academic institutions and biopharma companies often enter collaborations with different cultures, incentives, timelines, expectations, and definitions of success. This panel will bring leaders from both sides of the table together for a candid discussion about what each needs from the other to create high-performing research alliances. Where do expectations diverge? What does industry wish academic partners better understood about its environment—and vice versa? When should alliance management enter the picture? And what separates collaborations that generate sustained value from those that stall despite promising science? |
|
|
2:00 - 4:00 |
Puppy Playground Take a break from the sessions and recharge with some puppy love! Stop by to pet, snuggle, and spend time with adorable puppies from Last Hope K9 Rescue while enjoying a little stress relief and a chance to reconnect with your playful side. It’s the perfect opportunity to step away from the agenda, unwind, and enjoy a few feel-good moments with some four-legged friends. |
|
|
2:05-2:35 |
Networking Break | |
|
2:35-3:15 |
BREAKOUTS | |
|
Track 1 AI, Digital Innovation & the Future of Alliance Management |
202 - Integrating AI into Alliance Management: Enhancing Tools and Practices Stefan Walke, PhD, CA-AM, Boehringer Ingelheim As AI becomes a vital component of alliance management, its application extends beyond ad-hoc experimentation. This session explores practical experiences in using AI across recurring alliance management activities, such as contract analysis, governance preparation, structured communication, and discussion synthesis. AI acts as a sparring partner or "second reader," enhancing clarity, consistency, and efficiency while maintaining human accountability. Demonstrations will show how AI reduces routine effort, supports stakeholder preparation, and facilitates access to alliance management knowledge. The session also examines AI's role in coaching alliance managers to refine discussion structures, challenge assumptions, and prepare for governance interactions. Attendees will learn to recognize where AI can support core activities, leverage AI to challenge assumptions, and strengthen key behaviors like clear communication and structured thinking. Overall, the session highlights embedding AI in daily alliance management to improve quality and execution. |
|
|
Track 2 Alliance Leadership & Value Creation |
302 - Alliance Leaders' Evolving Mandate: Owning Value Realization
Jan Twombly, CSAP, CA-AM, The Rhythm of Business Enterprising life science alliance leaders are expanding their roles beyond governance and stakeholder orchestration, recognizing that value does not materialize on its own. Proficient and purposeful execution is essential, and alliance leaders are now central to this process. This session demonstrates how the profession is embracing its value realization mandate across the entire product lifecycle. Drawing on over 20 years of data and experiences from complex biopharma partnerships, we provide specific examples of how alliance leaders engineer value realization using simple tools that expose misalignment and create opportunities for realignment. We illustrate how alliance leaders reduce risk through consistent operating discipline and mobilize the enterprise to perform in a partner-dependent model. Participants will leave with practical tools to strengthen execution and deliver the promised value of their alliances. Attendees will learn to engineer operating discipline that drives real value, use practical tools to spot misalignment early, and apply methods to engage the enterprise in a partner-dependent strategy and operating model. |
|
|
Track 3 Complex Partnerships, Governance & Cross Sector Collaborations |
402 - From Silos to Synergy: Effective Governance for siRNA Innovation Amy Arthur, PhD, ADARx, and Allison Hoch, PhD, AbbVie The collaboration between AbbVie and ADARx combines AbbVie's expertise in biotherapeutic development and commercialization with ADARx's proprietary RNA platform to advance next-generation siRNA therapeutics across neuroscience, immunology, and oncology. This session explores governance models designed to manage a multi-therapeutic-area collaboration while maintaining focused, efficient decision-making. Speakers will discuss how governance forums are structured to remain lean and aligned with the most advanced asset or critical program inflection point, allowing later-stage program learnings to inform best practices for earlier-stage assets. Participants will learn practical approaches for steering complex collaborations, balancing strategic oversight with operational agility, and fostering cross-functional alignment. The session will also cover strategies for managing risk and accelerating the delivery of innovative siRNA therapies within a highly integrated partnership environment. Attendees will gain insights into governance practices that balance rigor with agility, enabling productive peer-to-peer relationships among subject matter experts while maintaining strategic alignment and accountability to shared partnership objectives. |
|
|
Track 4 Global Collaboration, Discovery Partnerships & Academia |
502 - Strategic Use of Alliance Management Best Practice Across Sectors Steve Andrews, PhD, University of Cambridge, Fiona Ducotterd, PhD, CSAP, CA-AM, ARUK Drug Discovery Institute, University College London, Fiona Jeganathan, PhD, ARUK Drug Discovery Institute, University College London, and Tryfon Zarganes-Tzitzikas, PhD, University of Oxford The Alzheimer's Research UK Drug Discovery Alliance exemplifies how cutting-edge academic drug discoveries can be transformed into impactful drug discovery projects applying industry process to accelerate promising discoveries towards patient solutions. Operating in academia with an industry mindset in structured collaboration frameworks with partners including academics, non-profits, funding bodies, service providers, healthcare sectors, and industry involves significant alliance capability. This session will discuss how alliance leadership facilitates complex cross-sector programs and accelerates research outcomes. Participants will learn to apply broad alliance management practices to turn opportunities into outcomes, understand the value of an outward mindset in cross-sector collaborations, and see how a unified vision and working model within alliances optimizes ways of working. |
|
|
3:15-3:25 |
Transition | |
|
3:25-4:05 |
BREAKOUTS | |
|
Track 1 AI, Digital Innovation & the Future of Alliance Management |
203 - Introducing MAESTRO: Building a Practical Digital Backbone for Modern Alliance Management Karen Berna, CSAP, CA-AM, Jazz Pharmaceuticals & Becky van den Honert, Jazz Pharmaceuticals Jazz Alliance Management and Digital Enterprise Capabilities have developed an AI tool, Maestro, launched in early 2026 to enhance transparency, insight, and coordination across complex collaborations and the entire alliance portfolio. This session will highlight the development planning and rationale for creating an internal tool, showcasing how Maestro proactively identifies risks, tracks value drivers, and accelerates alliance managers' research and analysis to support daily workflows. We will discuss coordination with corporate AI strategy and oversight councils to ensure compliance and security alignment. Lessons learned from implementation, including change management, data harmonization, and stakeholder adoption, will be shared, along with insights on scaling digital innovation in a live portfolio. Participants will gain a tangible framework for collaborating with internal stakeholders to leverage AI and elevate alliance performance. Attendees will learn about alliance management collaboration with internal technology teams, implementation lessons, and information security and compliance considerations. |
|
|
Track 2 Alliance Leadership & Value Creation |
303 - Who Leads When No One Is in Charge? The Alliance Manager's Role in Shaping Leadership in 50:50 Collaborations Andi Gardner, PharmD, CA-AM, Biogen, and Jennifer Berg, Supernus Pharmaceuticals Most 50:50 alliances are built on the premise of shared power, yet many still struggle with stalled decisions, recurring conflict, and misalignment. Why? Because governance does not lead alliances-people do. In partnerships where neither company has the authority to dictate outcomes, success depends on leaders who can influence without control, align without hierarchy, and maintain trust when interests diverge. At the center of this challenge is a relationship that often determines alliance success: the partnership between Governance Co-Chairs and the Alliance Manager.||This session challenges the notion that Alliance Managers are merely facilitators. Drawing on real-world biopharmaceutical case studies, we will explore how Alliance Managers act as architects of alliance leadership-shaping co-chair effectiveness, fostering trust, and creating the conditions for collaborative decision-making. Participants will leave with practical lessons, a leadership framework, and actionable tools to strengthen governance effectiveness when no one is in charge and influence is everything. |
|
|
Track 3 Complex Partnerships, Governance & Cross Sector Collaborations |
403 - The Next Frontier for Alliance Management: Maximizing the Value of Strategic Partners |
|
|
Track 4 Global Collaboration, Discovery Partnerships & Academia |
503 - Designing an Ecosystem for Impact: The LifeArc-CF Trust Translational Innovation Hub Thunicia Moodely, PhD, CA-AM, LifeArc, and Rebecca Wilson, PhD, CA-AM, LifeArc This session explores how alliance management can accelerate impact in rare diseases by embedding cross-organizational teams within a purpose-built ecosystem. Using the LifeArc-Cystic Fibrosis Trust Translational Innovation Hub as a case study, we demonstrate how structured collaboration across multiple academic institutions aligns scientific leadership, optimizes limited research funding, and drives translation in areas of persistent unmet need. Participants will learn how charities and co-funders collaborate with academics to design effective academic ecosystems. The session will highlight how effective governance and clear processes facilitate operational excellence, enabling not only program delivery but also capability building. This approach develops the next generation of researchers while compounding scientific and translational outcomes across partners. Attendees will gain insights into optimizing research and fostering impactful collaborations. |
|
|
4:05-4:15 |
Transition | |
|
4:15-4:55 |
BREAKOUTS | |
|
Track 1 AI, Digital Innovation & the Future of Alliance Management |
204 - GA Catalyst AI: Reshaping the Alliance Leader's Role with AI |
|
|
Track 2 Alliance Leadership & Value Creation |
304 - Sustainable Alliance Management: People-First Leadership for Success Niccolo Ciuffi, CA-AM, mAbxience Successful alliances rely on trust, engagement, and quality human interactions, not just strategy and governance. Sustainable Alliance Management emphasizes a people-first approach, recognizing communication, energy, and relationships as core drivers of long-term success. This session shares real-world experiences where the human dimension determined outcomes, such as transforming challenging partnerships and addressing burnout through shared ownership. Participants will learn to apply stakeholder psychology and people-first leadership to manage complex dynamics, adapt communication styles across organizational levels, and leverage strong relationships with Alliance Management counterparts. These strategies enhance team dynamics, prevent burnout, and drive sustainable business outcomes, ultimately benefiting individuals and organizations alike. Attendees will gain actionable tools to improve engagement, accelerate problem-solving, and create alliances that are sustainable for people and organizations. |
|
|
Track 3 Complex Partnerships, Governance & Cross Sector Collaborations |
404 - The Alliance Behind the Alliance: Aligning Internally to Deliver Externally Jessica Goodman, PhD, CSAP, CA-AM, Takeda, Andrew Ferguson, PhD, CA-AM, Takeda, Neha Garg, PhD, Derek Smith, Takeda, and Aaron Welch, Takeda As biopharma deals grow larger and more complex, the internal operating model behind each partnership increasingly determines its success. This panel introduces a two-function model at Takeda, emphasizing that the strength of an external alliance relies on the internal alliance supporting it. The R&D Asset Transition & Integration Office (RATIO) leads operational transitions, while Global Alliance Management (GAM) provides strategic oversight. Together, they present a unified face to partners. Panelists will discuss how this model works, the evolution of responsibilities, essential alignment points, and common challenges. Participants will learn to differentiate roles, map internal responsibilities, apply lessons to their organizations, and anticipate integration stumbling blocks. |
|
|
Track 4 Global Collaboration, Discovery Partnerships & Academia |
504 - One Partner, Multiple Interfaces: Delivering One Alliance Experience Lauren Bautista, Bristol Myers Squibb, and Melissa Nifenecker, Bristol Myers Squibb As biopharma partnerships expand across manufacturing and supply networks, the traditional single alliance leader model is no longer sufficient to deliver end-to-end value. This session introduces a practical dual-layer alliance management approach that integrates Global Alliance Management with Product Development & Supply (PDS) Alliance Management. Drawing on real-world lessons, speakers will demonstrate how clearly defined roles, governance, and decision rights align deal strategy with manufacturing and supply execution. Attendees will learn how to reduce organizational complexity, strengthen cross-functional collaboration, and create a seamless "one company" partner experience from negotiation through commercial supply. |
|
|
4:55-8:30 |
Free time to enjoy partner and team dinners in the city | |
|
8:30-10:00 |
After Glow Reception (all invited) Sponsored by Vantage Partners Join us for an evening of magic, sweet treats, and a little surprise! Get up close with an incredible close-up magician, enjoy delicious sweets and a signature drink, and enter the raffle hosted by Vantage Partners for a chance to win one of two one-hour sessions for up to eight people. It’s the perfect way to unwind, connect, and keep the conference magic going! |
|
| 6:15 - 7:15 | Morning Yoga - Free Activity Rise and Renew with a calming morning yoga session led by Swati Prasad. Mats are provided-just bring your breath and start your day with intention. Space is limited to 20 participants. Sign up under Networking Add-Ons in the conference registration |
| 7:00-8:15 | Networking Breakfast |
| 7:15 - 8:15 | Career Development Peer Group Breakfast Join ASAP Career Development Working Group co-chairs Katherine Ellison, CA-AM, of Illumina, and Brian Stewart, CA-AM, of Daiichi Sankyo, for an informal breakfast and conversation about career development in alliance management. Share your experiences and challenges, and discuss mentoring, job opportunities, and education pathways. The conversation will also include a short demonstration of Mentor Match, a Higher Logic platform that helps members find mentors and connect with others who can offer guidance and share their experience. Your input will help the Working Group identify areas of interest and opportunities for future career development resources. All conference attendees are welcome! |
|
|
DAY 3: THE FUTURE OF PARTNERSHIPS |
|
8:15-8:20 |
WELCOME BACK Katherine Kendrick, CSAP, CA-AM, Jazz, and Arne Wőrn, PhD, Novartis |
|
8:20-9:10 |
111 - Alliance Discussion Groups Alliance Discussion Groups offer a chance to connect with fellow alliance professionals around topics that matter most to you. Choose from multiple facilitator-led discussions, share experiences and perspectives with peers, and after 25 minutes, decide whether to move to a new topic or stay and continue the conversation.
|
|
9:10-9:40 |
112 - The Next Generation of Alliance Leadership: Building the Capabilities That Will Shape the Future The alliance profession is entering one of the most transformative periods in its history. Advances in artificial intelligence, increasingly complex partnership models, cross-sector collaboration, and new approaches to innovation are redefining the role of alliance management across the biopharma industry.
Building on the themes explored throughout the conference, Ed Cox will examine how the profession is evolving and the capabilities that will define successful alliance organizations in the years ahead. Drawing on decades of experience leading complex strategic partnerships across biopharma, digital health, and emerging technologies, he will share his perspective on how alliance professionals can strengthen trust, influence strategic decisions, navigate increasing complexity, and become indispensable drivers of innovation and business value.
Attendees will leave with a clear vision of where the profession is headed, the leadership capabilities organizations should be investing in today, and how alliance managers can position themselves to lead the next generation of strategic partnerships.
|
|
9:40-10:25 |
113 - The Clinic as Catalyst: Rethinking Partnership Across the Innovation Life Cycle The next generation of healthcare innovation will not be created or delivered by any one organization alone. As the boundaries between academia, healthcare, biotechnology, technology, investment, and industry continue to blur, the traditional partnership playbook must evolve. If the way innovation is discovered, developed, and delivered has changed, why should we expect yesterday’s partnership models to get us there? In this fireside conversation, Chris and Kevin will examine the partnership imperative from both sides of the innovation equation: those creating and commercializing clinical breakthroughs, and biopharma organizations seeking to bring them to scale. They will explore how collaboration models are being challenged, how organizations move innovation across institutional boundaries, and what distinguishes partnerships capable of turning great science into meaningful healthcare systems outcomes. |
|
10:25-10:40 |
Networking Break |
|
10:40-11:20 |
BREAKOUTS |
|
Track 1 AI, Digital Innovation & the Future of Alliance Management |
205 - AI + EQ: The Human Edge in an AI-Driven Alliance World
As AI transforms alliance management, the most effective alliance professionals will be those who know when to leverage AI—and when to lead with human judgment. This interactive session explores how Alliance Managers can use AI-enabled tools to streamline routine work, generate insights, and improve decision support while focusing their time on the uniquely human skills that drive successful partnerships. Through practical examples and facilitated discussion, attendees will examine how emotional intelligence, trust-building, stakeholder influence, and strategic decision-making remain essential in navigating complex collaborations. Participants will leave with a practical framework for balancing AI "autopilot" with human "mission control," enabling them to increase efficiency, strengthen partner relationships, and create greater strategic value in an increasingly AI-driven alliance landscape. Matt Brosnan, CA-AM, Takeda, and Rita Galhano, PhD, CA-AM, EMD Serono |
|
Track 2 Alliance Leadership & Value Creation |
305 - Navigating Role Clarity and Accountability in Strategic Alliances Anna Skabeev, MD, CA-AM, Teva Pharmaceuticals In complex strategic alliances, clearly defined roles and responsibilities are essential but not always sufficient. When one partner perceives underperformance, it can trigger disruptive behavior, such as encroachment into the other party's scope. These actions, often driven by urgency, can erode trust, create duplication, and weaken the alliance. This session explores the challenges of maintaining role clarity while enabling agility. Drawing on practical experience in alliance management and cross-company collaboration, we examine how organizations can balance accountability and partnership. Participants will learn to identify early signals of role breakdown, understand risks of scope encroachment, apply governance tools effectively, implement collaboration models, and foster trust and transparency in high-pressure situations |
|
Track 3 Complex Partnerships, Governance & Cross Sector Collaborations |
405 - Building a Scalable Clinical Supply Agreement Process Amid Rapid Growth: Establishing an Industry Standard |
|
Track 4 Global Collaboration, Discovery Partnerships & Academia |
505 - Navigating Cross‑Border Alliances in Emerging Markets Moderator: Jan Twombly, CSAP, CA-AM, The Rhythm of Business Panelists: Jason Powell, AbbVie, Ashley Snyder, PharmD, Everest Medicines, and Brian Stewart, CA-AM, Daiichi Sankyo Cross‑border alliances in emerging markets—especially China, India, Southeast Asia, and Latin America—are becoming essential to biopharma growth and innovation. Yet these partnerships operate in environments defined by regulatory complexity, evolving IP norms, cultural differences, and rapidly shifting commercial landscapes. This panel brings together experienced alliance leaders to explore how global and local partners can navigate development and commercialization challenges, protect IP, manage regulatory uncertainty, and build trust‑based relationships that move beyond transactional deal execution. Through practical examples and candid insights, panelists will discuss what it takes to strengthen strategic alignment, accelerate joint decision making, and unlock long‑term value in alliances across emerging markets. |
|
11:20-11:30 |
Transition |
|
11:30-12:10 |
BREAKOUTS |
|
Track 1 The Future of AI & Alliance Intelligence |
206 - AI and Alliance Management: Enhancing Partnership Leadership Without Losing Critical Thinking Adam Kornetsky, Vantage Partners, and Logan Grubb, Vantage Partners |
|
Track 2 The Human Future of Alliances |
306 - The Wild Card: Managing Disruptive Influences in Partnerships Katherine Ellison, CA-AM, Illumina, Maegan Harden, PhD, CA-AM, Illumina, and Holly Lakin, CA-AM, Illumina Alliance Managers often work with professional teams, but occasionally encounter a "wild card"—an individual whose comments, actions, or expectations can derail a partnership. Colleagues look to Alliance Managers to resolve these disruptions, whether the wild card is within their organization or the partner's. Neutralizing such influences requires skill, influence, and leadership. In this session, a panel of experts will discuss the impact of wild cards on partnerships, strategies to navigate their disruptions, and how to use Alliance Management fundamentals to mitigate future risks. Participants will learn to mitigate human risks, prepare teams for challenging interactions, and recover partnerships knocked off track by disruptive individuals. |
|
Track 3 The Future of Technology, Risk & Value |
406 - From Risk to Return: Maximizing IT Value for AM Elnaz Atabakhsh PhD, AstraZeneca, and Ajit Acharya, PhD, AstraZeneca In a rapidly evolving IT landscape, how can alliance directors translate technology into measurable value?
This session examines the impact of data and fit for purpose AI on Alliance Management. Through case studies, we will showcase how to secure, scale, and streamline collaboration, safeguard data integrity and mobility to mitigate risks, and the role that AI tools can play in amplifying value to alliance professionals.
|
|
Track 4 The Future of Alliance Leadership |
506 - The Evolving Role of Alliance Management in Biopharma Aura Fratian, Xencor, Samuel Gosselin, CA-AM & Pamela Rodriguez, PhD, Bristol Myers Squibb Ask any alliance leader what keeps them up at night, and while deal terms may come up, it's often the hallway conversation, someone still asking what alliance management actually does. This session is three unscripted stories about why that question persists and what it costs. A governance committee that broke, and the fallout when the function's value wasn't understood at the table. A function built from ad-hoc coverage into a well-defined strategic hub, and what that took. A portfolio stretched across early-stage research to commercial launch at once, and the constant mode-shifting it demanded. Together, they show what strategic alliance leadership looks like when it works, and what's lost when it's misread or under-resourced. Come curious: this isn't your usual panel, and the takeaways are real. |
| 12:20-12:55 |
114 - The Road Ahead: Three Predictions. One Challenge. The Future of Strategic Alliances As the closing session of the conference, this panel looks at where biopharma alliances are headed. Panelists will make three predictions about the forces reshaping the industry, from China’s growing role in innovation to AI to pricing and market-access pressures, and put one challenge to the alliance professionals in the room. Drawing on experience from companies of different sizes and markets, panelists will discuss how these changes affect alliance formation, management, and long-term success, and what alliance professionals can do now to prepare for the next five years. |
| 12:55-1:05 | Closing & Invite to 2027 BioPharma Boston, Tracy Blois, PhD, Amgen, Nicole Boston, CAE, CA-AM, ASAP, Katherine Kendrick, CSAP, CA-AM, Jazz, Petra Sansom, PhD, Beam Therapeutics, and Arne Wőrn, PhD, Novartis |
| 1:05 | Boxed Lunch |
| 2:00-4:30 | Walk, Connect & Explore Boston Extend your BioPharma Boston experience with a relaxed, guided walking tour through historic streets, connecting with fellow ASAP attendees along the way. The tour concludes with a happy hour drink, a great way to unwind and enjoy the city before heading home. Minimum 6 participants; maximum 20. An additional fee applies. Sign up under Networking Add-Ons in the conference registration. |
“ASAP’s BioPharma Conference is unequivocally the most valuable event I attend each year. The rich content and community elevate my career and alliance capabilities."
Logistics
Venue & Room Block
Renaissance Boston Seaport District
606 Congress Street, Boston, MA 02210
Block opening soon
ASAP has secured discounted room rate of $289+ per/night (until October 9, 2027 or when the block is full).
Justification Letter
To help secure approval for your participation, customize this letter.
"The ASAP BioPharma Conference is a transformative experience that brings together the brightest minds in the industry. The insights and connects are invaluable."
2026 Sponsors
We’re grateful to our sponsors whose support makes this event possible and strengthens the entire ASAP community. Their partnership enables us to deliver meaningful programs and experiences throughout the year. Interested in becoming an ASAP sponsor? Visit our sponsorship page to learn more and connect with us.
Platinum Level

Gold Level

Silver Level

Bronze Level
